Canada markets closed

Cardiol Therapeutics Inc. (CRDL.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
2.9800-0.0600 (-1.97%)
At close: 04:00PM EDT
Full screen
Previous Close3.0400
Bid2.9700 x 0
Ask2.9800 x 0
Day's Range2.9700 - 3.1900
52 Week Range0.8900 - 3.2700
Avg. Volume141,209
Market Cap205.615M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.4700
Earnings DateAug 08, 2024 - Aug 12, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024

    Scope of presentation included trial design, rationale, and blinded baseline data on first 50 patients randomized into the Phase II study evaluating CardiolRx™ in patients with acute myocarditis ARCHER trial rationale and design also accepted for publication in the journal ESC Heart FailureARCHER trial has now exceeded 85% of target patient enrollment MAvERIC-Pilot Phase II study investigating CardiolRx™ for recurrent pericarditis expected to report topline results in early June 2024Toronto, Ont

  • Newsfile

    Cardiol Therapeutics Announces Year-End 2023 Update on Operations

    Completed patient enrollment in the Phase II MAvERIC-Pilot study evaluating CardiolRx™ in patients withrecurrent pericarditis, with topline results expected in Q2 2024CardiolRx™ granted U.S. FDA Orphan Drug Designation for the treatment of pericarditis,which includes recurrent pericarditisExceeded 50% enrollment in the Phase II ARCHER trial evaluating CardiolRx™in patients with acute myocarditis; study expected to reach full enrollment during Q3 2024Data presented at the HFSA Annual Scientific S

  • Newsfile

    Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

    Topline Results Expected in Q2 2024 This is a Designated News Release.Toronto, Ontario--(Newsfile Corp. - February 21, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced completion of patient enrollment in its Phase II open-label pilot study ("MAvERIC-Pilot") investigati